Italia markets closed

QIAGEN N.V. (QGEN)

NYSE - NYSE Prezzo differito. Valuta in USD.
Aggiungi a portafoglio
48,69-0,88 (-1,78%)
Alla chiusura: 04:00PM EST
48,69 0,00 (0,00%)
Dopo ore: 04:43PM EST

QIAGEN N.V.

Hulsterweg 82
Venlo 5912 PL
Netherlands
31 77 355 6600
https://www.qiagen.com

Settore/iHealthcare
SettoreDiagnostics & Research
Impiegati a tempo pieno6.000

Figure dirigenziali chiave

NomeTitoloRetribuzioneEsercitateAnno di nascita
Mr. Thierry BernardCEO, MD & Member of Management Board2,41MN/D1965
Dr. Roland SackersCFO, MD & Member of Management Board977,5kN/D1968
Dr. Barthold PieningSr. VP & Head of Global OperationsN/DN/D1958
Mr. John GilardiVP of Corp. Communications & Investor RelationsN/DN/DN/D
Ms. Stephany FosterSr. VP & Head of HRN/DN/DN/D
Dr. Thomas SchweinsSr. VP of Life Science Bus. AreaN/DN/DN/D
Dr. Thomas TheuringerSr. Director & Head of External CommunicationsN/DN/DN/D
Mr. Jean-Pascal ViolaSr. VP, Head of Molecular Diagnostics Bus. Area & Corp. Bus. Devel.N/DN/DN/D
Dr. Jonathan G. Sheldon Ph.D.Sr. VP of Qiagen Digital Insights Bus. AreaN/DN/D1972
Mr. Thomas NeidertVP of Global TreasuryN/DN/DN/D
Gli importi risalgono al giorno 31 dicembre 2020 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories. It also provides interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; assays for analysis of genomic variants; and assays for prenatal testing and detection of sexually transmitted diseases and HPV; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers PCR consumables, such as quantitative PCR, reverse transcription and combinations kits for analysis of gene expression, genotyping and gene regulation instruments and technologies; human ID and forensics assay consumables, including STR assays for human ID, and assays for food contamination; PCR instruments consist of digital PCR solutions; and developed and configured OEM consumables. It offers predefined and custom NGS gene panels, library prep kits and components, whole genome amplification, etc.; bioinformatics solutions; and custom laboratory and genomic services. It serves molecular diagnostics, academia, pharmaceutical, and applied testing customers. The company has collaboration agreements with Amgen Inc.; CLIA-certified laboratories; NuProbe Global; and Personal Genome Diagnostics Inc., as well as a strategic alliance agreement with Sysmex Corporation. The company was founded in 1986 and is headquartered in Venlo, the Netherlands.

Governance aziendale

L'ISS Governance QualityScore di QIAGEN N.V. al 26 settembre 2021 è 5. I criteri di valutazione fondamentali sono revisione: 5; Consiglio di Amministrazione: 3; diritti degli azionisti: 9; retribuzione: 5.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.